Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Menopausal status does not predict Oncotype DX recurrence score.

The Journal of surgical research - 1 Sept 2015

Carr Danielle N, Vera Nora, Sun Weihong, Lee Marie Catherine, Hoover Susan, Fulp William, Acs Geza, Laronga Christine

Abstract excerpt

BACKGROUND: Adjuvant treatment for early stage, estrogen receptor (ER) positive invasive breast cancer has been based on prognosticators such as menopausal status. The recurrence score (RS) from the 21-gene assay Oncotype DX (ODX) is predictive of a 10-y distant recurrence in this population but is rarely applied to premenopausal patients. The relationship between menopausal status and RS was evaluated. MATERIALS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Breast Neoplasms
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Menopause

Share to Neoplasm Recurrence, Local

Share to Receptor, ErbB-2

Share to Receptors, Estrogen

Source

Identifiers

PMID: 26095420
DOI: 10.1016/j.jss.2015.05.034

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Menopausal status does not predict Oncotype DX recurrence score.PMID 26095420Read ↗

Clinical outcomes and Oncotype DX Breast Recurrence Score® in early-stage BRCA-associated hormone receptor-positive breast cancer.Semantic proximity Read ↗

Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations.Semantic proximity Read ↗

Correlation between the Clinical Treatment Score Post 5 years (CTS5) and the Oncotype DX 21-gene recurrence score (ODX-RS); can we accurately predict patients who require extended adjuvant hormonal manipulation.Semantic proximity Read ↗

Favorable Locoregional Control in Clinically Node- Negative Hormone-receptor Positive Breast Cancer With Low 21-gene Recurrence Scores: a Single Institutional Study With 10-year Follow-upSemantic proximity Read ↗

Associations Between the 21-Gene Oncotype DX Recurrence Score, Ki67, and Race in Early Breast Cancer: An Analysis of the National Cancer DatabaseSemantic proximity Read ↗

Utility of the 21-Gene Recurrence Score in Node-Positive Breast Cancer.Semantic proximity Read ↗

Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.Semantic proximity Read ↗

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancerSemantic proximity Read ↗

Impact of genomic testing and patient-reported outcomes on receipt of adjuvant chemotherapy.Semantic proximity Read ↗

Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009.Semantic proximity Read ↗

Evaluating the Association of Ki 67 with Oncotype DX Recurrence Score in Early-Stage ER Positive/HER2 Negative Breast CancerSemantic proximity Read ↗

The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in KoreaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.